Alcohol health and research world, 22(3), 211219
GLP-1 receptor agonistsanother promising therapy for Alport syndrome
Results vary by individual and are not guaranteed
in subjects with baseline A1c 9%, (respectively, 16 in the oral semaglutide and 25 in the subcutaneous semaglutide group) the delta A1c was 3.3% for both formulations ( p = 0.9, data not shown), consistently with previous findings of greater efficacy in patients with higher baseline A1c values
Combined with the appetite suppression from GLP-1 and the insulin sensitivity improvements from GIP, you get a stronger total effect
Dual peptide blends allow researchers to evaluate interactions across multiple signaling pathways simultaneously, offering insight into complex biochemical and structural processes under controlled experimental conditions